Last updated: 2026-09-09 04:52:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Foghorn Therapeutics Inc. (FHTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4,83, with a market capitalisation of $292,18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,27 to $7,61. This page covers its latest market performance, valuation, price trends and company information.
$292,18M | |
$4,81 | |
$28,27 | |
$2,70 | |
$4,92 | |
189,43K | |
326,96K | |
-- | |
$7,61 | |
$3,27 | |
-- | |
-- |
Foghorn Therapeutics Inc. (FHTX) last closed at $4,92 as of 2026-09-08 23:31:00, unchanged from the previous close of $4,92.
During the latest regular trading session, FHTX traded between $2,70 and $28,27, with a volume of 189,43K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Foghorn Therapeutics Inc. (FHTX) moved from $6,22 to $4,83, representing a decline of 22,33% ($1,39).
The stock traded between $4,70 and $6,80 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 427,59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 36,0%
FHTX is currently trading at $4,83, placing it 36,0% of the way from its 52-week low of $3,27 to its 52-week high of $7,61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 106 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Foghorn Therapeutics Inc. (FHTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.